Clinical Trials Logo

Clinical Trial Summary

The trial is performed to asses efficacy and safety of a sublingual extract of a six grass pollen mixture


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00264459
Study type Interventional
Source Allergopharma GmbH & Co. KG
Contact
Status Completed
Phase Phase 3
Start date February 2003
Completion date September 2011

See also
  Status Clinical Trial Phase
Recruiting NCT05560698 - A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment N/A
Completed NCT01445002 - Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy Phase 2
Completed NCT01830673 - Regulatory T-cells After Subcutaneous Immunotherapy N/A
Active, not recruiting NCT04502966 - Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction Phase 2
Completed NCT00263601 - Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis Phase 3
Completed NCT01538979 - Phase II Study of Grass Pollen Allergy Vaccine BM32 Phase 2
Completed NCT04435678 - Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens N/A
Completed NCT01308021 - Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis Phase 2
Completed NCT00773240 - A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment Phase 3